BXP:LSE-Beximco Pharmaceuticals Limited (GBX)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | LSE

Last Closing Price

GBX 82.50

Change

0.00 (0.00)%

Market Cap

GBX 0.36B

Volume

1.30K

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Beximco Pharmaceuticals Limited (BXP) Stock Analysis:
Based on the Beximco Pharmaceuticals Limited stock forecasts from 0 analysts, the average analyst target price for Beximco Pharmaceuticals Limited is not available over the next 12 months. Beximco Pharmaceuticals Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Beximco Pharmaceuticals Limited is Very Bullish, which is based on 13 positive signals and 0 negative signals. At the last closing, Beximco Pharmaceuticals Limited’s stock price was GBX 82.50. Beximco Pharmaceuticals Limited’s stock price has changed by +2.48% over the past week, -16.67% over the past month and +1.23% over the last year.

No recent analyst target price found for Beximco Pharmaceuticals Limited
No recent average analyst rating found for Beximco Pharmaceuticals Limited

About

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous s ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HIK:LSE Hikma Pharmaceuticals PLC

-68.50 (-3.90%)

GBX3.92B 12.11 5.47
INDV:LSE Indivior PLC

-9.20 (-2.86%)

GBX2.27B 17.49 6.88
HCM:LSE HUTCHMED (China) Limited

-10.40 (-6.67%)

GBX1.35B 17.41 N/A
APH:LSE Alliance Pharma plc

-0.40 (-0.36%)

GBX0.61B 86.62 18.00
AMYT:LSE Amryt Pharma plc

N/A

GBX0.46B N/A 260.86
BMK:LSE Benchmark Holdings plc

+0.40 (+0.82%)

GBX0.37B N/A 13.53
ANCR:LSE Animalcare Group plc

N/A

GBX0.18B 3,350.00 19.10
AGY:LSE Allergy Therapeutics plc

N/A

GBX0.14B 53.13 364.98
EAH:LSE ECO Animal Health Group plc

N/A

GBX0.08B 14.94 3.22
VLG:LSE Venture Life Group plc

-1.50 (-4.62%)

GBX0.04B 18.33 9.29

ETFs Containing BXP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -32.10% 40% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.10% 40% F 14% F
Trailing 12 Months  
Capital Gain 1.23% 79% C+ 70% C-
Dividend Return 0.05% 100% A+ 64% D
Total Return 1.28% 79% C+ 70% C-
Trailing 5 Years  
Capital Gain 24.06% 86% B 64% D
Dividend Return 7.23% 83% B 39% F
Total Return 31.29% 86% B 65% D
Average Annual (5 Year Horizon)  
Capital Gain 20.96% 79% C+ 79% C+
Dividend Return 2.02% 100% A+ 68% D+
Total Return 22.97% 79% C+ 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 52.46% 57% F 26% F
Risk Adjusted Return 43.78% 79% C+ 63% D
Market Capitalization 0.36B 67% D+ 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.12 90% A- 58% F
Price/Book Ratio 1.00 73% C 61% D-
Price / Cash Flow Ratio 0.06 60% D- 76% C
EV/EBITDA 0.09 100% A+ 99% A+
Management Effectiveness  
Return on Equity 14.23% 87% B+ 52% F
Return on Invested Capital 11.94% 80% B- 74% C
Return on Assets 7.32% 87% B+ 74% C
Debt to Equity Ratio 2.63% 100% A+ 90% A-
Technical Ratios  
Dividend Yield 3.55% 100% A+ 67% D+
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.83 47% F 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:

There is nothing we particularly dislike